LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 15, 2006--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that it has enrolled and dosed the first patient in its Phase I/II clinical trial of intravenous (IV) zileuton in patients with asthma. The double-blind, placebo-controlled, single-dose trial is being conducted at multiple centers in the United States.
